Drugs & Aging

, Volume 15, Issue 6, pp 451–460 | Cite as

Colony-Stimulating Factors in the Treatment of Older Patients with Acute Myelogenous Leukaemia

  • Simon Bolam
  • Terry Hamblin
Review Article


The treatment of acute myelogenous leukaemia (AML) in the elderly is a difficult and increasing problem. The elderly are generally less able to tolerate the intensive chemotherapy required to achieve a sustained remission, and there is an increased incidence of resistant disease in this age group. Granulocyte- and granulocyte-macrophage colony-stimulating factors have been demonstrated to shorten the duration of severe neutropenia following chemotherapy for solid tumours and after bone marrow/peripheral blood stem cell transplantation, and the effect of these growth factors in the treatment of AML has been investigated in a number of trials using 2 distinct strategies. Growth factors may be administered following chemotherapy in an attempt to accelerate neutrophil recovery, and they may be given before and during chemotherapy with the aim to increase the number of leukaemic blast cells in cell cycle and enhance their responsiveness to chemotherapy. Both of these approaches have proved safe despite initial theoretical concerns regarding the expression of receptors for these growth factors on leukaemic cells. The results of trials using these growth factors in the treatment of AML in the elderly generally show a significant reduction in the duration of neutropenia following induction chemotherapy. However, consistent benefits with respect to morbidity and early mortality together with improvements in long term disease outcome have not been observed. The ‘priming’ approach using growth factors before and during induction chemotherapy has proved equally disappointing in failing to improve response rates or survival. The routine use of these growth factors in the treatment of AML in the elderly population as a whole would, therefore, not seem to be cost effective.


Adis International Limited Cytarabine Acute Myeloid Leukaemia Acute Myelogenous Leukaemia Leukaemic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brinkler H. Population based age- and sex-specific incidence rates in the four main types of leukaemia. Scand J Haematol 1982; 29: 241–9Google Scholar
  2. 2.
    Rees JKH, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet 1986; II: 1236–41CrossRefGoogle Scholar
  3. 3.
    Peterson BA. Acute non-lymphocytic leukaemia in the elderly: biology and treatment. In: Blomfield CD, editor. Adult leukaemias I. The Hague: Martins Nijhoff, 1982: 199–235CrossRefGoogle Scholar
  4. 4.
    Estey E, Smith TL, Keating MJ, et al. Prediction of survival during induction therapy in patents with newly diagnosed acute myeloblastic leukaemia. Leukaemia 1989; 3: 257–63Google Scholar
  5. 5.
    Swirsky DM, De Bastos M, Parish SE, et al. Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br J Haematol 1986; 64: 435–53PubMedCrossRefGoogle Scholar
  6. 6.
    Avorn J, Gurwitz JH. Principles of pharmacology. In: Cassel CK, Cohen G, Larsen E, editors. Geriatric medicine. 3rd ed. New York (NY): Springer, 1997Google Scholar
  7. 7.
    Estey EH, Keating MJ, McCredie KB, et al. Causes of initial remission induction failure in acute myelogenous leukaemia. Blood 1982; 60: 309–15PubMedGoogle Scholar
  8. 8.
    Tucker J, Thomas AE, Gregory WM, et al. Acute myeloid leukaemia in elderly adults. Haematol Oncol 1990; 8: 13–21CrossRefGoogle Scholar
  9. 9.
    Johnson PRE, Liu Yin JA. The incidence of clinical or morphological myelodysplasia on the outcome of therapy in elderly patients with acute myeloid leukaemia [abstract]. Haematologica 1991; 76 Suppl. 4: 511aGoogle Scholar
  10. 10.
    Hamblin T. The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome. Leuk Res 1992; 16: 101–8PubMedCrossRefGoogle Scholar
  11. 11.
    Bernard P, Reiffers J, Lacombe F, et al. Prognostic value of age and bone marrow karyotype in 78 adults with acute myelogenous leukaemia. Cancer Genet Cytogenet 1982; 7: 153–63PubMedCrossRefGoogle Scholar
  12. 12.
    Swansbury GJ, Lawler SD, Alimena G, et al. Long term survival in acute myelogenous leukaemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukaemia. Cancer Genet Cytogenet 1994; 73: 1–7PubMedCrossRefGoogle Scholar
  13. 13.
    Fialkow PJ, Singer JW, Raskin WH, et al. Clonal development, stem cell differentiation, and clinical remissions in acute non lymphocytic leukaemia. N Engl J Med 1987; 317: 468–73PubMedCrossRefGoogle Scholar
  14. 14.
    Greaves MF. Stem cell origins of leukaemia and curability. Br J Cancer 1993; 67: 413–23PubMedCrossRefGoogle Scholar
  15. 15.
    Wood P, Burgess R, MacGregor A, et al. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509–14PubMedCrossRefGoogle Scholar
  16. 16.
    Bernard P, Reiffers J, Lacombe F, et al. A stage classification in adult acute myelogenous leukaemia based upon patient’s age, bone marrow karyotype and clinical features. Scand J Haematol 1984; 32: 429–40PubMedCrossRefGoogle Scholar
  17. 17.
    Johnson PRE, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993; 85: 300–6PubMedCrossRefGoogle Scholar
  18. 18.
    Holmes FF, Hearne E, Conant M, et al. Survival in the elderly with acute leukaemia. J Am Geriatr Soc 1979; 27: 241–3PubMedGoogle Scholar
  19. 19.
    Kahn SB, Begg CB, Mazza JJ, et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute non-lymphocytic leukaemia in the elderly. J Clin Oncol 1984; 2: 865–70PubMedGoogle Scholar
  20. 20.
    Lieschke GJ, Burgess AW. Drug therapy: granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor. N Engl J Med 1992; 327 (2 Pt 2): 99–106PubMedCrossRefGoogle Scholar
  21. 21.
    Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64–9PubMedCrossRefGoogle Scholar
  22. 22.
    Stieff CA, Emerson SG, Donahue RE, et al. Human recombinant granulocyte-macrophage colony stimulating factor: a multilineage haemopoietin. Science 1985; 230: 1171–3CrossRefGoogle Scholar
  23. 23.
    Cebon J, Nicola N, Ward M, et al. Granulocyte-macrophage colony stimulating factor from human lymphocytes: the effect of glycosylation on receptor binding and biological activity. J Biol Chem 1990; 265: 4483–91PubMedGoogle Scholar
  24. 24.
    Lowenberg B, Touw IP. Haemopoietic growth factors and their receptors in acute leukaemia. Blood 1993; 81: 281–92PubMedGoogle Scholar
  25. 25.
    Delwel R, Salem M, Pelens C, et al. Growth regulation of human acute myeloid leukaemia: effects of five recombinant haemopoietic factors in a serum-free culture system. Blood 1988; 72: 1944–9PubMedGoogle Scholar
  26. 26.
    Baer MR, Bernstein SH, Brunetto VL, et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukaemia. Blood 1996; 87: 1484–94PubMedGoogle Scholar
  27. 27.
    le Boekhorst PAW, Lowenberg B, Vlastuin M, et al. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukaemia by G-CSF, IL-3 or GM-CSF stimulation. Leukaemia 1993; 7: 1191–8Google Scholar
  28. 28.
    Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte-colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukaemia. N Engl J Med 1990; 323: 871–7PubMedCrossRefGoogle Scholar
  29. 29.
    Estey EH, Dixon D, Kanterjian HM, et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukaemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75 (9): 1766–9PubMedGoogle Scholar
  30. 30.
    Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukaemia at higher age or after relapse. Blood 1991; 78: 1190–7PubMedGoogle Scholar
  31. 31.
    Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukaemia. Blood 1991; 77: 700–11PubMedGoogle Scholar
  32. 32.
    Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukaemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–55PubMedGoogle Scholar
  33. 33.
    Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukaemia. Leukemia 1993; 7: 372–7PubMedGoogle Scholar
  34. 34.
    Buchner T, Hiddemann W, Wormann B, et al. The role of GMCSF in the treatment of acute myeloid leukaemia. Leuk Lymphoma 1993; 11 Suppl. 2: 21–4PubMedCrossRefGoogle Scholar
  35. 35.
    Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction therapy in refractory acute myeloid leukaemia. Blood 1994; 83: 2086–92PubMedGoogle Scholar
  36. 36.
    Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–8PubMedGoogle Scholar
  37. 37.
    Buchner T, Hiddemann W, Wormann B, et al. GM-CSF multiple course priming and long-term administration in newly diagnosed AML: haematologic and therapeutic effects [abstract]. Blood 1994; 84 Suppl. 1: 27aGoogle Scholar
  38. 38.
    Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. N Engl J Med 1995; 332: 1671–7PubMedCrossRefGoogle Scholar
  39. 39.
    Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukaemia. N Engl J Med 1995; 332: 1678–83PubMedCrossRefGoogle Scholar
  40. 40.
    Rowe JM, Andersen JW, Mazza JJ, et al. Arandomised placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457–62PubMedGoogle Scholar
  41. 41.
    Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukaemia (AML). Leukemia 1995; 9: 3–9PubMedGoogle Scholar
  42. 42.
    Godwin JE, Kopecky KJ, Head DR, et al. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukaemia: a Southwest Oncology Group study [abstract]. Blood 1995; 86 Suppl. 1: 434aGoogle Scholar
  43. 43.
    Lowenberg B, Boogaerts MA, Vellenga E, et al. Various modalities of use of GM-CSF in the treatment of acute myelogenous leukaemia (AML): a Hovon-Sakk randomized study (Hovon4A) [abstract]. Blood 1995; 86 Suppl. 1: 512aGoogle Scholar
  44. 44.
    Heil G, Hoelzer D, Sanz MA, et al. Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukaemia [abstract] Blood 1995; 86 Suppl. 1: 267aGoogle Scholar
  45. 45.
    Witz F, Harousseau JL, Sadoun A, et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukaemia (AML) [abstract]. Br J Haematol 1996; 93 Suppl. 2: 134Google Scholar
  46. 46.
    Maslak PG, Weiss MA, Berman E, et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukaemia. Leukemia 1996; 10: 32–9PubMedGoogle Scholar
  47. 47.
    Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukaemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150–9PubMedGoogle Scholar
  48. 48.
    Lowenberg B, Suciu S, Archimbaud G, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952–61PubMedGoogle Scholar
  49. 49.
    Smith MA, Singer CRJ, Pallister CJ, et al. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematol 1995; 90: 767–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Department of HaematologyRoyal Bournemouth HospitalBournemouthEngland

Personalised recommendations